Pediatric Study Of Leuprolide Test, Obesity Devices To Be Discussed By Committee
This article was originally published in The Pink Sheet Daily
Protocol for leuprolide (TAP's Lupron) test of puberty disorders rejected by University of Chicago IRB to be reviewed by FDA's Pediatric Ethics Subcommittee.
You may also be interested in...
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.